How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?
We discuss all that and more on this week’s episode of “The Readout LOUD,” a weekly biotech podcast from STAT.
Advertisement
Adam is out this week, so Allison and Elaine dive into the latest news, starting with another biotech acquisition and a new CEO at GSK. Then, they invite health policy researcher Stacie Dusetzina to break down President Trump’s “most-favored nation” pricing deal with Pfizer.
For more details on the Pfizer drug pricing agreement, go here; to learn more about GSK’s new CEO and Emma Walmsley’s departure, go here; to read about George Tidmarsh’s lupus drug criticism, go here; and for more on the Merus acquisition, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.